Children’s Hospital of Philadelphia was recognized specifically for significant contributions to the development of a new treatment for a certain pediatric leukemia.

The European Commission (EC) approves Kymriah, the first-ever U.S. FDA approved personalized CAR T-cell gene immunotherapy for aggressive blood cancers.

A leading pediatric oncologist at CHOP, Dr. Grupp is now Chief of the Section of Cellular Therapy and Transplant in the Hospital’s Division of Oncology.

Emily Whitehead, the first pediatric patient to receive CAR T-cell therapy, and her family honor the CHOP team who saved her life with a $250,000 research grant to expand the use of the therapy for relapsed or refractory ALL.

Updated results from a global clinical trial of the CAR T-cell therapy for ALL reveal that children and young adults continued to show high rates of durable, complete remission of their disease.

CHOP has been at the forefront of developing cell therapy to treat ALL. Some next steps include initiating clinical trials for AML and, ultimately, making this treatment work for solid tumors.

Philanthropy helped CHOP develop the first cell therapy to receive FDA approval and provide lifesaving treatments to 170 children with ALL, like Paulina.

The FDA approval of Kymriah™ has shifted the paradigm for pediatric cancer treatment — and at Children's Hospital of Philadelphia, more cell therapies are on the horizon.

This is a game changer for the treatment of pediatric patients battling leukemia and a pivotal milestone in this new era of cellular therapies that treat cancer with a patient’s own immune system.

Five years after her T-cell therapy for ALL, Emily remains cancer-free. CHOP has since treated more than 170 patients in clinical trials that have seen a 93% remission rate.